← Back to Patent Explorer
US5756678A Expired / Lapsed US ⏱️ 0.0 years remaining

Prion inactivation in connective tissue materials

Assignee: Angiotech Pharmaceuticals Inc
•
Filing: 1995-05-01
•
Granted: 1998-05-26
•
Expires: 2015-05-01
📄 Original PDF 🌐 Google Patents 🔄 Sync Now

Abstract

Abstract It has been discovered that it is possible to treat solutions of connective tissue material for the inactivation of prions in a manner such that connective tissue molecules are not adversely affected by the inactivation treatment. For example, solubilized atelopeptide collagen can be treated with sodium hydroxide for the inactivation of prions and other infectious agents without affecting the ability of the solubilized collagen to form stable fibers. In accordance with the present invention, a first method for the treatment of connective tissue materials such as collagen for the inactivation of prions and other infective agents, to obtain at least 5 logs of protection, comprises the following steps: a) placing the connective tissue material into a liquid solution, whereby the surface area of the connective tissue molecules is exposed, to expose the prions and other infectious agents for treatment; and b) contacting the liquid solution of connective tissue material with sodium hydroxide so that the concentration of sodium hydroxide in said solution ranges from about 0.1M to about 0.7M, for a time period sufficient to inactivate the prions and other infective agents without affecting the performance of the connective tissue material, at a temperature of about 25 DEG C. or less.

Inventors

  • 👤 Vivek N. Shenoy
  • 👤 Timothy T. Revak

Bibliographic Details

Application Number —
Jurisdiction US
Data Source google_patents
Last Synchronized 2026-11-06 14:08
CPC Classifications
A; A61; A61L; A61L2/00; A61L2/16; A61L2/18

Claims Analysis

Total Claims: 20
Claim 1
Independent Claim 94 words
A method for treatment of solubilized collagen to inactivate prions and other infective agents, comprising: contacting solubilized collagen with sodium hydroxide in a liquid solution, whereby surface area of the solubilized collagen molecules is exposed, to expose prions and other infectious agents for treatment, wherein sodium hydroxide in said liquid solution ranges in concentration from about 0.1M to about 0.35M, for a time period sufficient to inactivate said prions and other infective agents, at a temperature of about 25° C. or less; wherein the collagen is capable of forming stable fibers after said inactivation.
Claim 2
Independent Claim 94 words
A method for treatment of solubilized collagen to inactivate prions and other infective agents, comprising: contacting solubilized collagen with sodium hydroxide in a liquid solution, whereby surface area of the solubilized collagen molecules is exposed, to expose prions and other infectious agents for treatment, wherein sodium hydroxide in said liquid solution ranges in concentration from about 0.1M to about 0.35M, for a time period sufficient to inactivate said prions and other infective agents, at a temperature of about 25° C. or less; wherein the collagen is capable of forming stable fibers after said inactivation.
Claim 3
Dependent Claim 13 words
The method of claim 1, wherein said time period is about 80 minutes.
Claim 4
Dependent Claim 13 words
The method of claim 1, wherein said time period is about 100 minutes.
Claim 5
Dependent Claim 13 words
The method of claim 1, wherein said time period is about 150 minutes.
Claim 6
Dependent Claim 11 words
The method of claim 1 wherein the collagen is atelopeptide collagen.
Claim 7
Dependent Claim 12 words
The method of claim 1 wherein the temperature is about 20° C.
Claim 8
Dependent Claim 12 words
The method of claim 1 wherein the temperature is about 25° C.
Claim 9
Dependent Claim 18 words
The method of claim 1 wherein the method is effective to inactivate at least 5 logs of infectivity.
Claim 10
Dependent Claim 15 words
The method of claim 1 wherein the concentration is about 0.25M to 0.35M sodium hydroxide.
Claim 11
Dependent Claim 13 words
The method of claim 1 wherein the concentration is about 0.25M sodium hydroxide.
Claim 12
Dependent Claim 13 words
The method of claim 1, wherein said time period is about 90 minutes.
Claim 13
Dependent Claim 12 words
The method of claim 11 wherein the temperature is about 20° C.
Claim 14
Dependent Claim 12 words
The method of claim 11 wherein the temperature is about 25° C.
Claim 15
Dependent Claim 18 words
The method of claim 1, wherein the concentration of sodium hydroxide in said liquid solution is about 0.1M.
Claim 16
Dependent Claim 11 words
The method of claim 14 wherein the collagen is atelopeptide collagen.
Claim 17
Dependent Claim 18 words
The method of claim 14 wherein the method is effective to inactivate at least 5 logs of infectivity.
Claim 18
Independent Claim 91 words
A method of inactivating prions in a collagen material, comprising a) solubilizing collagen in a liquid solution, whereby surface area of the solubilized collagen molecules is exposed, to expose prions; and b) contacting the collagen in the liquid solution with sodium hydroxide, such that the concentration of sodium hydroxide in said liquid solution ranges from about 0.1M to about 0.35M, for a time period sufficient to inactivate said prions, at a temperature of about 25° C. or less, and wherein the collagen is capable of forming stable fibers after said inactivation.
Claim 19
Independent Claim 91 words
A method of inactivating prions in a collagen material, comprising a) solubilizing collagen in a liquid solution, whereby surface area of the solubilized collagen molecules is exposed, to expose prions; and b) contacting the collagen in the liquid solution with sodium hydroxide, such that the concentration of sodium hydroxide in said liquid solution ranges from about 0.1M to about 0.35M, for a time period sufficient to inactivate said prions, at a temperature of about 25° C. or less, and wherein the collagen is capable of forming stable fibers after said inactivation.
Claim 20
Dependent Claim 11 words
The method of claim 17 wherein the collagen is atelopeptide collagen.

References Cited (Backward Citations)

US3131130A Cited
US3530037A Cited
US4511653A Cited
CA2140834A1 Cited
EP0667352A1 Cited
US5616689A Cited

USPTO Annuity & Maintenance Windows

Annuity Stage Window Opens Payment Deadline Surcharge Period Until Estimated Fee Status
3.5 Years (Year 4) 2001-05-25 2001-11-24 2002-05-26 $2000.00 Window Closed / Lapsed
7.5 Years (Year 8) 2005-05-25 2005-11-24 2006-05-26 $3760.00 Window Closed / Lapsed
11.5 Years (Year 12) 2009-05-25 2009-11-24 2010-05-26 $7700.00 Window Closed / Lapsed

Assigned Categories & Tags

No categories assigned to this patent yet.

Assign Category Tag